Please check your internet connection and try again.
# Lorazepam (Representative Benzodiazepine)
## Overview
Lorazepam is a short-acting benzodiazepine with anxiolytic, sedative, hypnotic, amnestic, anticonvulsant, and skeletal muscle relaxant properties. It is metabolized by glucuronidation, which is less affected by liver disease compared to other benzodiazepines.
## Primary Indications
* Insomnia
* Anxiety disorders
* Status epilepticus (acute seizure management)
* Preoperative sedation
## Adult Dosing
* **Insomnia:** 2-4 mg at bedtime.
* **Anxiety Disorders:** 1-3 mg orally 2-3 times daily. Maximum daily dose is typically 10 mg.
* **Status Epilepticus:** 2-4 mg IV/IM initially. May repeat every 5-10 minutes as needed, up to a maximum of 8 mg in a 12-hour period.
* **Preoperative Sedation:** 2-4 mg IM 2 hours before surgery or 2-4 mg IV 15-30 minutes before induction.
## Pediatric Dosing
* **Status Epilepticus:** 0.1 mg/kg IV/IM, not to exceed 4 mg per dose. May repeat every 5-10 minutes as needed, up to a maximum dose of 0.1 mg/kg or 8 mg total (whichever is less).
* **Anxiety/Sedation:** Dosing is highly variable and depends on the indication. Often initiated at lower doses (e.g., 0.02-0.1 mg/kg/dose) and titrated carefully. No universally established standard doses for chronic anxiety treatment in pediatrics; use is generally off-label and cautious.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is generally needed due to glucuronidation metabolism. However, caution is advised, and lower doses may be appropriate.
* **Renal Impairment:** No dose adjustment is generally needed. However, caution is advised, and lower doses may be appropriate.
* **Elderly:** Start with lower doses (e.g., 1-2 mg once daily for insomnia, 1 mg twice daily for anxiety) and titrate cautiously due to increased sensitivity to CNS effects.
## Contraindications
* Hypersensitivity to lorazepam or other benzodiazepines.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis (relative contraindication).
* Sleep apnea syndrome.
## Adverse Effects
Common: Drowsiness, dizziness, weakness, ataxia, sedation, confusion.
Less Common: Paradoxical excitation, amnesia, visual disturbances, hypotension, respiratory depression (especially with IV administration or in combination with other CNS depressants).
## Key Drug Interactions
* **CNS Depressants (opioids, alcohol, other sedatives/hypnotics, antipsychotics, antihistamines):** Additive CNS depression, increased risk of sedation, respiratory depression, coma, and death.
* **Theophylline, Aminophylline:** May reduce the sedative effects of lorazepam.
* **Valproic Acid:** May increase lorazepam plasma concentrations.
## Monitoring
* Assess for sedation, dizziness, and cognitive impairment.
* Monitor respiratory rate and oxygen saturation, especially with IV administration or in combination with other respiratory depressants.
* Evaluate for paradoxical reactions.
* Monitor for signs of withdrawal if used chronically and discontinued abruptly.
## Clinical Pearls
* Lorazepam is available in oral, IM, and IV formulations. The IM route offers predictable absorption. IV administration should be slow to minimize adverse effects.
* Avoid concomitant use with opioids if possible due to risk of severe respiratory depression and death. If co-administration is necessary, use the lowest effective doses and shortest duration, and monitor closely.
* Long-term use can lead to physical and psychological dependence. Gradual tapering is recommended upon discontinuation.
* Intranasal and rectal formulations exist for emergency use (e.g., seizure clusters) and may be preferred in settings where IV access is difficult or delayed.
***
*Disclaimer: This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient management decisions. Dosing and recommendations may vary based on institutional protocols and individual patient factors.*
